{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:21:39Z","timestamp":1787163699752,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,29]]},"DOI":"10.7759\/cureus.85067","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T02:30:12Z","timestamp":1748572212000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer and Autoimmune Diseases"],"prefix":"10.7759","author":[{"given":"Kenta","family":"Takashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhito","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Matuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.024","article-title":"How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis","volume":"115","author":"Khan SA","year":"2018","unstructured":"Khan SA, Pruitt SL, Xuan L, Makris U, Gerber DE. How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis. Lung Cancer. 2018, 115:97-102. 10.1016\/j.lungcan.2017.11.024","journal-title":"Lung Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2023.24.1.331","article-title":"Exclusion of patients with autoimmune disease in lung cancer clinical trials","volume":"24","author":"Khan SS","year":"2023","unstructured":"Khan SS, Komiya T. Exclusion of patients with autoimmune disease in lung cancer clinical trials. Asian Pac J Cancer Prev. 2023, 24:331-6. 10.31557\/APJCP.2023.24.1.331","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.29917","article-title":"Lung cancer survival in patients with autoimmune disease","volume":"3","author":"Jacob S","year":"2020","unstructured":"Jacob S, Rahbari K, Tegtmeyer K, et al.. Lung cancer survival in patients with autoimmune disease. JAMA Netw Open. 2020, 3:e2029917. 10.1001\/jamanetworkopen.2020.29917","journal-title":"JAMA Netw Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei H","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al.. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015, 373:1627-39. 10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer J","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al.. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015, 373:123-35. 10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE- 010): a randomised controlled trial","volume":"387","author":"Herbst RS","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, et al.. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE- 010): a randomised controlled trial. Lancet. 2016, 387:1540-50. 10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia SJ","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, et al.. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017, 377:1919-29. 10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer A","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, et al.. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017, 389:255-65. 10.1016\/S0140-6736(16)32517-X","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi L","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al.. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018, 378:2078-92. 10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares L","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, et al.. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018, 379:2040-51. 10.1056\/NEJMoa1810865","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn L","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, et al.. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018, 379:2220-9. 10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.05.006","article-title":"Safety and efficacy of immune checkpoint inhibitors in cancer patients and preexisting autoimmune disease: a systematic review and meta-analysis in non-small-cell lung cancer","volume":"24","author":"Aung WY","year":"2023","unstructured":"Aung WY, Lee CS, Morales J, Rahman H, Seetharamu N. Safety and efficacy of immune checkpoint inhibitors in cancer patients and preexisting autoimmune disease: a systematic review and meta-analysis in non-small-cell lung cancer. Clin Lung Cancer. 2023, 24:598-612. 10.1016\/j.cllc.2023.05.006","journal-title":"Clin Lung Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison A","year":"2019","unstructured":"Tison A, Qu\u00e9r\u00e9 G, Misery L, et al.. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019, 71:2100-11. 10.1002\/art.41068","journal-title":"Arthritis Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107894","article-title":"Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)","volume":"194","author":"Asao T","year":"2024","unstructured":"Asao T, Shukuya T, Uemura K, et al.. Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047). Lung Cancer. 2024, 194:107894. 10.1016\/j.lungcan.2024.107894","journal-title":"Lung Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies AM","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, et al.. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017, 28:368-76. 10.1093\/annonc\/mdw443","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00137","article-title":"Efficacy and toxicity of immune-checkpoint inhibitors in patients with preexisting autoimmune disorders","volume":"7","author":"Coureau M","year":"2020","unstructured":"Coureau M, Meert AP, Berghmans T, Grigoriu B. Efficacy and toxicity of immune-checkpoint inhibitors in patients with preexisting autoimmune disorders. Front Med (Lausanne). 2020, 7:137. 10.3389\/fmed.2020.00137","journal-title":"Front Med (Lausanne)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab N","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018, 168:121-30. 10.7326\/M17-2073","journal-title":"Ann Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study","volume":"24","author":"Cortellini A","year":"2019","unstructured":"Cortellini A, Buti S, Santini D, et al.. Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist. 2019, 24:e327-37. 10.1634\/theoncologist.2018-0618","journal-title":"Oncologist"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.01.014","article-title":"Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies","volume":"130","author":"Yoneshima Y","year":"2019","unstructured":"Yoneshima Y, Tanaka K, Shiraishi Y, et al.. Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies. Lung Cancer. 2019, 130:5-9. 10.1016\/j.lungcan.2019.01.014","journal-title":"Lung Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi Y","year":"2019","unstructured":"Toi Y, Sugawara S, Sugisaka J, et al.. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol. 2019, 5:376-83. 10.1001\/jamaoncol.2018.5860","journal-title":"JAMA Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2204754","article-title":"Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)","volume":"12","author":"Daban A","year":"2023","unstructured":"Daban A, Gonnin C, Phan L, et al.. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs). Oncoimmunology. 2023, 12:2204754. 10.1080\/2162402X.2023.2204754","journal-title":"Oncoimmunology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-823912-4.00022-0","article-title":"Paraneoplastic myopathies","volume":"200","author":"Mammen AL","year":"2024","unstructured":"Mammen AL. Paraneoplastic myopathies. Handb Clin Neurol. 2024, 200:327-32. 10.1016\/B978-0-12-823912-4.00022-0","journal-title":"Handb Clin Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/365334-efficacy-and-immune-related-adverse-events-of-immune-checkpoint-inhibitors-in-patients-with-non-small-cell-lung-cancer-and-autoimmune-diseases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T02:30:12Z","timestamp":1748572212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/365334-efficacy-and-immune-related-adverse-events-of-immune-checkpoint-inhibitors-in-patients-with-non-small-cell-lung-cancer-and-autoimmune-diseases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.85067","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,29]]}}}